Skip to content
Wednesday, August 26, 2026
1 WOMEN'S HEALTHWOMEN'S & REPRODUCTIVE HEALTH

Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer

Women's Health Trial Tracker organizes records from ClinicalTrials.gov API v2 into a static table for transparent comparison. It preserves official source links and dates, marks missing enrichment, and adds deterministic grouping, change, recency, trend, or significance fields only where the documented inputs support them, without recommendations or unsupported claims.

Records
5,000
Last changed
Update schedule
55 1 * * * UTC
Coverage
05/26/2000–08/25/2026
Method
Methodology
Title
Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer
Record Date
05/26/2023
Vuga Group
OBSERVATIONAL
Change Status
unchanged
Recency Days
1,188.85
Public Significance Score
0